In June 2003, Curis established a collaboration with Genentech for the development of a set of technologies based on inhibition of the Hedgehog signaling pathway, including small molecule Hedgehog pathway inhibitors.
Genentech’s support of Curis personnel and other third-party resources dedicated to the collaboration was due to terminate in June 2005. The amended agreement provides for a six-month extension of support for Curis personnel with an option for an additional six-month extension.
Curis has successfully used its technology and product development approach to produce several promising drug product candidates in the fields of cancer, kidney disease, neurological disorders, hair growth, and cardiovascular disease. These drug candidates have resulted from collaborations with several major industry players including Johnson and Johnson and Wyeth, as well as Genentech.